LeMaitre Vascular, Inc.
NASDAQ:LMATMedical - Instruments & Supplies
+$1.60 today
- Market cap
- $1.73B
- Beta
- 0.52
- P/E (TTM)
- 34.3
- EPS (TTM)
- $2.74
- Dividend yield
- 0.96%
Volume 0.22M
Average 0.26M
LMAT EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
LeMaitre Vascular, Inc.NASDAQ: LMAT
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA grows in line with its trailing trend
Q1 FY2026 EBITDA of $23.6M rose 30.5% year over year, behind the +31.7% change in trailing-twelve-month EBITDA. Sequentially, it fell 2.5% from the prior quarter. Over 3 fiscal years it compounded at +35.0% a year.
Context
- EBITDA amounted to 36.4% of revenue in FY2025, up 6.0 pp from a year earlier.
- EBITDA increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 6 analysts of $96.37M (+6.1%) for the fiscal year ending Dec 2026, a slowdown from the +36.0% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $23.6M-2.5% QoQ
- Last fiscal yearDec 2025
- $90.79M+36.0% YoY
- LTMMar 2026
- $96.3M+31.7% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +30.5% | +28.1% | -2.4 pp |
| 1 year | +36.0% | +6.1% | -29.9 pp |
| 3-year CAGR | +35.0% | +8.8% | -26.1 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- 90.79M USD
- Year-over-year change
- +36.0%
- 4-year CAGR
- +18.5%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 90.79M | +36.0% |
| FY2024 | 2024-12-31 | 66.75M | +36.3% |
| FY2023 | 2023-12-31 | 48.99M | +32.7% |
| FY2022 | 2022-12-31 | 36.92M | -19.7% |
| FY2021 | 2021-12-31 | 45.98M | — |
EBITDA vs competitors
How LMAT compares with its peers on the latest reported figures
- LMAT's LTM Mar 2026 EBITDA of $96.3M is the 5th highest of the 8 companies compared; the peer median is $222.27M.
- Its year-over-year change of +31.7% is the 2nd highest of 8, against a peer median of +9.8%.
- EBITDA amounts to 37.6% of revenue for LMAT, versus a peer median of 14.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jul 2026 | $10.27B | +9.8% | +4.1% | 27.3% | |
| LTM Jun 2026 | $5.8B | +23.2% | +23.0% | 27.6% | |
| LTM Sep 2026 | $341.34M | +9.0% | +22.4% | 21.2% | |
| LTM Jun 2026 | $222.27M | +14.8% | +95.5% | 14.8% | |
| LTM Mar 2026 | $96.3M | +31.7% | +35.0% | 37.6% | |
| LTM Mar 2026 | $65.05M | +84.5% | +35.4% | 14.2% | |
| LTM Feb 2026 | -$5.44M | -1089.6% | -46.2% | 1.7% | |
| LTM Jun 2026 | -$158.49M | -126.4% | -25.5% | 6.1% | |
| Peer median (excluding LMAT) | $222.27M | +9.8% | +22.4% | 14.8% | |
Competitors are the stored peer set for LMAT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 154.42M | 161.65M | 193.48M | 219.86M | 249.6M |
| Cost of Revenue | 53.04M | 56.76M | 66.44M | 68.96M | 71.06M |
| Gross Profit | 101.38M | 104.9M | 127.05M | 150.9M | 178.54M |
| Gross Margin | 65.7% | 64.9% | 65.7% | 68.6% | 71.5% |
| Research & Development | 11.8M | 13.29M | 16.97M | 15.65M | 14.14M |
| Selling, General & Admin | 53.16M | 61.67M | 72.89M | 83M | 96.49M |
| Operating Expenses | 64.96M | 78.07M | 90.34M | 98.65M | 110.63M |
| Depreciation & Amortization | 9.48M | 9.43M | 9.52M | 9.67M | 10.42M |
| EBITDA | 45.98M | 36.92M | 48.99M | 66.75M | 90.79M |
| EBITDA Margin | 29.8% | 22.8% | 25.3% | 30.4% | 36.4% |
| Operating Income | 36.43M | 26.83M | 36.71M | 52.26M | 67.91M |
| Operating Margin | 23.6% | 16.6% | 19.0% | 23.8% | 27.2% |
| Interest Income | 197K | 986K | 3.08M | 4.95M | 13.09M |
| Interest Expense | 2.22M | 0 | 0 | 205K | 5.18M |
| Other Income / Expenses | (2.14M) | 661K | 2.76M | 4.62M | 7.27M |
| Income Before Tax | 34.29M | 27.49M | 39.48M | 56.88M | 75.18M |
| Pre-Tax Margin | 22.2% | 17.0% | 20.4% | 25.9% | 30.1% |
| Income Tax Expense | 7.38M | 6.85M | 9.37M | 12.84M | 17.45M |
| Net Income | 26.91M | 20.64M | 30.11M | 44.04M | 57.73M |
| Net Margin | 17.4% | 12.8% | 15.6% | 20.0% | 23.1% |
| EPS (Basic) | 1.27 | 0.94 | 1.36 | 1.96 | 2.55 |
| EPS (Diluted) | 1.25 | 0.93 | 1.34 | 1.93 | 2.52 |
| Weighted Avg Shares | 21.16M | 21.98M | 22.22M | 22.45M | 22.64M |
| Weighted Avg Shares (Diluted) | 21.48M | 22.17M | 22.42M | 22.78M | 22.93M |
LeMaitre Vascular, Inc.
NASDAQ:LMAT
Intrinsic Alpha fair value
Locked
Current Price
$75.58
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.